Oneness Biotech Co Ltd (4743) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Oneness Biotech Co Ltd TWD 9.92, price TWD 45.15, upside -78.0%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Oneness Biotech Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 41.75 TWD – 286.83 TWD · fair‑value band 6.55 TWD – 12.40 TWD · the 45.15 TWD price screens above the 9.92 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Oneness Biotech Co in your weekly email
Every Wednesday you see whether Oneness Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments.
Show more
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
Stock analysis
Oneness Biotech Co Ltd (4743) currently trades at 45.15 TWD, while our model-based Fair Value estimate is 9.92 TWD, implying the stock looks roughly 355.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the evidence level at low.
Scenario range: 6.55 TWD (bear) to 12.40 TWD (bull), the price of 45.15 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Oneness Biotech Co Ltd reported revenue of 129M TWD in FY2025 versus 65.8M TWD in FY2021, a compound +18.4%/yr. Reported net income was −1.0B TWD in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 40% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −78%, 4743 screens richer than that median.
Fair Value models
Bear 6.55 TWDFair Value 9.92 TWDBull 12.40 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−50.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.4%
Start year 2020 (pandemic). Over 10 years: +32.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−588.3% (2020) → −618.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside−78% · Bottom 25%
Profitability
Return on assets−4% · Above median
Growth and dividend
Revenue growth45% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.07× · Cheapest 25%
P/S (TTM)4.84× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oneness Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4743
Frequently asked questions
Is Oneness Biotech Co Ltd (4743) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 9.92 TWD versus a price of 45.15 TWD, about −78% upside (overvalued).
What is the fair value of 4743?
Our model-based fair value for Oneness Biotech Co Ltd is 9.92 TWD (as of Sep 23, 2026), built from audited fundamentals. The current price: 45.15 TWD.
What is the quality score of 4743?
Oneness Biotech Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oneness Biotech Co Ltd (4743)?
Our model-based price target is the fair value of 9.92 TWD (as of Sep 23, 2026) from 1 valuation models. Cautious scenario 6.55 TWD, optimistic scenario 12.40 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Oneness Biotech Co Ltd stock forecast for 2026?
Our models put fair value at 9.92 TWD, about −78% upside versus a price of 45.15 TWD (overvalued). Cautious scenario 6.55 TWD, optimistic scenario 12.40 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Oneness Biotech Co Ltd (4743)?
Oneness Biotech Co Ltd reported trailing-twelve-month revenue of about 141M TWD (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Oneness Biotech Co Ltd (4743)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oneness Biotech Co Ltd it is 9.92 TWD per share (as of Sep 23, 2026), against a price of 45.15 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oneness Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 4743 trades above its calculated fair value: price 45.15 TWD, fair value 9.92 TWD, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4743?
No. The price is what the market pays today (45.15 TWD); the fair value is what the company's own numbers justify (9.92 TWD). For Oneness Biotech Co Ltd the two are 35.23 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Oneness Biotech Co Ltd worth?
The market values Oneness Biotech Co Ltd at about 21.6B TWD (market capitalisation, as of Sep 23, 2026). Per share that is 45.15 TWD; our models calculate a fair value of 9.92 TWD per share.
What do the bullish and bearish scenarios say about 4743?
Our models span a range for Oneness Biotech Co Ltd: cautious scenario 6.55 TWD, base 9.92 TWD, optimistic 12.40 TWD per share (as of Sep 23, 2026, price 45.15 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oneness Biotech Co Ltd (4743)?
Balance-sheet figures for Oneness Biotech Co Ltd (as of Sep 23, 2026): return on equity −9.4%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 4743 from its 52-week high?
Oneness Biotech Co Ltd trades at 45.15 TWD, about 40% below its 52-week high of 74.80 TWD and 8% above the low of 41.75 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 9.92 TWD is for.
Which stocks are comparable to Oneness Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oneness Biotech Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price 45.15 TWD, calculated fair value 9.92 TWD (−78%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4743 calculated?
We run Oneness Biotech Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.92 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Oneness Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oneness Biotech Co Ltd (4743)?
The closing price on Sep 23, 2026 was 45.15 TWD. Our model-based fair value is 9.92 TWD, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oneness Biotech Co Ltd right now?
The price sits above even our optimistic bull case (12.40 TWD). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.55 TWD to 12.40 TWD) leaves room in how you read the outcome.
Key figures of Oneness Biotech Co Ltd
How large is the market capitalisation of Oneness Biotech Co Ltd (4743)?
The market capitalisation of Oneness Biotech Co Ltd is 21.6B TWD (≈ $679M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Oneness Biotech Co Ltd (4743)?
Earnings per share at Oneness Biotech Co Ltd are −2.15 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Oneness Biotech Co Ltd (4743)?
The return on equity (ROE) of Oneness Biotech Co Ltd is −9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oneness Biotech Co Ltd (4743)?
On an EBIT basis the return on assets of Oneness Biotech Co Ltd is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oneness Biotech Co Ltd (4743)?
The operating margin of Oneness Biotech Co Ltd is −524% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oneness Biotech Co Ltd (4743)?
Revenue at Oneness Biotech Co Ltd is growing +45.2% versus a year earlier (3y avg −50.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oneness Biotech Co Ltd (4743)?
Earnings per share at Oneness Biotech Co Ltd are growing +219% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oneness Biotech Co Ltd (4743) generate?
The free cash flow of Oneness Biotech Co Ltd is −487M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oneness Biotech Co Ltd (4743) hold?
Oneness Biotech Co Ltd holds more cash than debt, 381M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Oneness Biotech Co Ltd in the live analysis
One click puts Oneness Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
